Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. ARWR
ARWR logo

ARWR

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

ARWR News

Arrowhead Pharmaceuticals Q2 2026 Earnings Call Highlights

2d agoseekingalpha

Arrowhead Pharmaceuticals to Participate in Multiple Upcoming Conferences

6d agoNewsfilter

Latest Wall Street Rating Updates

May 01 2026CNBC

REDEMPLO Approved in Australia for FCS Treatment

May 01 2026Newsfilter

Arrowhead Pharmaceuticals' Redemplo Receives Positive EMA Recommendation

Apr 24 2026stocktwits

US Stocks Rise on Strong Retail Sales and Earnings Reports

Apr 21 2026NASDAQ.COM

U.S. Stocks Mixed as Oil Prices Rebound

Apr 21 2026NASDAQ.COM

US Stocks Close Lower as Oil Prices Rebound Impact Market

Apr 21 2026NASDAQ.COM

Morgan Stanley Upgrades Arrowhead to Overweight with $100 Target

Apr 21 2026seekingalpha

Arrowhead Pharmaceuticals Stock Outlook Optimistic

Apr 21 2026CNBC

Latest Wall Street Ratings Overview

Apr 21 2026CNBC

Arrowhead's Plozasiran Significantly Reduces TG Levels in Hypertriglyceridemia Patients

Mar 28 2026Newsfilter

Ionis Pharmaceuticals Lowers Tryngolza Price to Enhance Competitive Positioning

Mar 26 2026Newsfilter

WVE-007 Trial Data Triggers Stock Volatility

Mar 26 2026stocktwits

Johnson & Johnson Divests from 3 Biotech Companies While Retaining Investments in Potential Acquisition Candidates

Mar 25 2026Barron's

AvaíBio Initiates α-Klotho Cell Bank Creation

Mar 24 2026PRnewswire